Topas Therapeutics GmbH

    Topas Therapeutics is developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti drug antibodies. Topas’ technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. Several proprietary programs are in R&D. The lead one is in an orphan disease and is expected to enter the clinic in 2019. Topas has a multi-year research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction, a multi-year agreement with Boehringer Ingelheim in the field of anti-drug antibodies and a co-development agreement with Evotec for a Type 1 diabetes program. The Company is backed by a group of highly successful life sciences investors.

     


    About Topas Therapeutics GmbH:

    Field of Activity Developing new therapeutic solutions for autoimmune diseases, allergies and anti-drug antibodies by leveraging the liver’s natural immunology capabilities.
    Ownership Structure and Financing Series A in 2016 (€14 million); additional €4 million in 2017. Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund
    Partners Eli Lilly and Company – antigen-specific tolerance induction Boehringer Ingelheim – anti-drug antibodies
    Evotec – co-development for Type 1 diabetes program
    Technology Topas’ technology platform harnesses the natural mechanisms of the liver to promote immune tolerance to blood borne antigens. Identified internal as well as external antigens, known to cause undesired effects, are coupled as peptides to Topas Particle Conjugates (TPCs)
    which mimic such blood borne antigens and are taken up by liver sinusoidal endothelial cells (LSECs). LSECs present these antigens to T cells under anti-inflammatory conditions conducive to the induction of tolerogenic regulatory T cells – pivotal for immune tolerance.
    Products/Services Orphan disease (expected to enter the clinic in 2019), ADA-1 (in vivo POC), Type 1 diabetes (in vivo POC), Celiac disease (discovery), Multiple sclerosis (to be partnered)
    Unique Selling Point First firm to leverage the liver’s natural and powerful tolerance induction capabilities: Induces immune tolerance by targeting liver sinusoidal endothelial cells.
    Date of Incorporation 2013
    Number of Employees 12


    Contact:


    Timm Jessen

    CEO

    ANZEIGE
    Telephone +49 40 47196-320
    E-Mail  info@topas-therapeutics.com

     

    Address:

    Topas Therapeutics GmbH
    Falkenried 88, Haus A
    20251 Hamburg

    Web Address:

    https://topas-therapeutics.com

     


    Articles of Allergy Therapeutics:

    14.09.2018: Topas Therapeutics erweitert Serie-A-Finanzierungsrunde
    23.03.2016: Topas erzielt Serie A-Finanzierung von 14 Mio. EUR

    Print Friendly, PDF & Email